Therapeutic efficacy of atovaquone against the bovine intraerythrocytic parasite, Babesia divergens.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Journal of Parasitology

• Publication date

  1997-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2307/3284461PMID 9105316
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful prevention and treatment of babesiosis with atovaquone.

  1995cited by this paper
• Atovaquone as prophylaxis against Pneumocystis carinii pneumonia.

  1994cited by this paper
• Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS.

  1993cited by this paper
• Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80).

  1992cited by this paper
• 566C80: a potent broad spectrum anti-infective agent with activity against malaria and opportunistic infections in AIDS patients.

  1991cited by this paper
• Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.

  1991cited by this paper
• Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii

  1991cited by this paper
• Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis

  1990cited by this paper
• [2 cases of severe human babesiosis treated successfully].

  1990cited by this paper
• Deux cas de babésiose humaine grave traités avec succès

  1990cited by this paper
• Novel anti-malarial hydroxynaphthoquinones with potent broad spectrum anti-protozoal activity

  1985cited by this paper
• Chemotherapy of Babesia divergens in the gerbil, Meriones unguiculatus.

  1983cited by this paper
• Plasmodium falciparum: rapid assay for in vitro inhibition due to human serum from residents of malarious areas.

  1982cited by this paper
• Successful chemotherapy of transfusion babesiosis.

  1982cited by this paper
• Babesiosis in man: Report of a case from scotland with observations on the infecting strain

  1979cited by this paper

• Persistence and Transmission Dynamics of Babesia ovis After Imidocarb Dipropionate Treatment: Evaluation via Blood Transfusion and Tick Infestation

  2025cites this paper
• 4‐nitrobenzoate inhibits 4‐hydroxybenzoate polyprenyltransferase in malaria parasites and enhances atovaquone efficacy

  2025cites this paper
• Targeting piroplasmosis and theileriosis: New frontiers in drug development

  2025cites this paper
• Comparative efficacy of buparvaquone and imidocarb in inhibiting the in vitro growth of Babesia bovis

  2024cites this paper
• Diminazene aceturate and imidocarb dipropionate-based combination therapy for babesiosis - A new paradigm.

  2023cites this paper
• The Etiology, Incidence, Pathogenesis, Diagnostics, and Treatment of Canine Babesiosis Caused by Babesia gibsoni Infection

  2022cites this paper
• Human Babesiosis in Europe

  2021cites this paper
• Treatment of Human Babesiosis: Then and Now

  2021cites this paper
• In vivo efficacy of combination therapy with albendazole and atovaquone against primary hydatid cysts in mice

  2021cites this paper
• Management strategies for human babesiosis

  2020cites this paper
• Mitochondrial complex III in larval stage of Echinococcus multilocularis as a potential chemotherapeutic target and in vivo efficacy of atovaquone against primary hydatid cysts.

  2020cites this paper
• Unravelling the cellular and molecular pathogenesis of bovine babesiosis: is the sky the limit?

  2019cites this paper
• Therapeutic management of canine babesiosis associated with acute renal failure

  2019cites this paper
• A fatal case of Babesia divergens infection in Northwestern Spain.

  2018cites this paper
• Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm

  2017influential citation
• Studies on the establishment of the treatment strategy with atovaquone for Babesia gibsoni infection in dogs

  2014cites this paper
• Studies on the establishment of the treatment strategy with atovaquone for Babesia gibsoni infection in dogs

  2014cites this paper
• Studies on molecular based diagnostic assay and clinico-pathobiochemical findings in Babesia bigemina infection in dairy animals

  2014cites this paper
• Babesia bovis Dihydroorotate Dehydrogenase (BboDHODH) is a Novel Molecular Target of Drug for Bovine Babesiosis

  2013cites this paper
• Human Babesiosis in Europe: what clinicians need to know

  2013cites this paper
• Apicoplast-Targeting Antibacterials Inhibit the Growth of Babesia Parasites

  2012cites this paper
• Development of in vitro atovaquone-resistant Babesia gibsoni with a single-nucleotide polymorphism in cytb.

  2012cites this paper
• Current Advances in Detection and Treatment of Babesiosis

  2012cites this paper
• Novel Diamidines with Activity against Babesia divergens In Vitro and Babesia microti In Vivo

  2011cites this paper
• In vitro growth inhibitory effect of (-)-Epigallocatechin-3-gallate from green tea on the growth of equine Babesia parasites

  2011cites this paper
• Artesunate, a potential drug for treatment of Babesia infection.

  2010cites this paper
• Zoonotic babesiosis: overview of the disease and novel aspects of pathogen identity.

  2010cites this paper
• Inhibitory effects of (-)-Epigallocatechin-3-gallate from green tea on the growth of Babesia parasites

  2009cites this paper
• Possible emergence of drug-resistant variants of Babesia gibsoni in clinical cases treated with atovaquone and azithromycin.

  2009cites this paper
• Babesiosis: recent insights into an ancient disease.

  2008cites this paper
• Short report: cloning of the Babesia gibsoni cytochrome B gene and isolation of three single nucleotide polymorphisms from parasites present after atovaquone treatment.

  2006cites this paper
• Canine Babesiosis: Epidemiological, Molecular and Therapeutic Investigations

  2004cites this paper
• Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs.

  2004cites this paper
• Malaria and the pregnant traveller.

  2004cites this paper
• Babesia sp.: emerging intracellular parasites in Europe.

  2004cites this paper
• Efficacy of atovaquone against Babesia gibsoni in vivo and in vitro.

  2004cites this paper
• Other protozoal infections

  2003cites this paper
• Babesia divergens, a Bovine Blood Parasite of Veterinary and Zoonotic Importance

  2003cites this paper
• Toxoplasma gondii: A Model for Evolutionary Genomics and Chemotherapy

  2002cites this paper
• Babesiosis in humans: a treatment review

  2002cites this paper
• Zoonotic babesiosis.

  2002cites this paper
• Antiparasitic Agent Atovaquone

  2002cites this paper
• Resistance as a tool in the study of old and new drug targets in Toxoplasma.

  2001cites this paper
• Human babesiosis: an emerging tick-borne disease.

  2000cites this paper
• Babesiosis

  2000cites this paper
• Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance.

  2000cites this paper
• Activity of atovaquone against Babesia microti in the Mongolian gerbil, Meriones unguiculatus.

  1999cites this paper
• Les babésioses humaines

  1998cites this paper
• Human babesiosis.

  1998cites this paper
• In Vitro Evaluation of Drug Susceptibilities of Babesia divergens Isolates

  1998cites this paper